ERYTECH Pharma S.A. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
49ERYTECH Pharma S.A.'s Business Model
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
About ERYTECH Pharma S.A.
Website: https://www.erytech.com
CEO (Chief Executive Officer): Mr. Gil Beyen M.B.A.
IPO date: 2016-07-05
Contact
Country: FR
Address: 60 Avenue Rockefeller
City: Lyon
State: None
Phone: 33 4 78 74 44 38
Zip Code: 69008
Other
CIK: 0001624422
ISIN: US29604W1080
CUSIP: 29604W108
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
